Mesoblast (MESO) EPS (Basic) (2014 - 2023)

Mesoblast (MESO) posted EPS (Basic) of -$0.06 for Q2 2023, down 17.45% sequentially from -$0.05 in Q1 2023, and up 10.3% YoY from -$0.05 in Q2 2022.

Analysis

Mesoblast (MESO) EPS (Basic) (2014 - 2023) Analysis & Trends

Mesoblast has reported EPS (Basic) for 10 years, with the latest figure at -$0.06 in Q2 2023.

Quarterly EPS (Basic) rose 10.3% year-over-year to -$0.06 in Q2 2023, while the trailing twelve-month figure through Dec 2024 was -$0.02 (up 74.87% YoY) and the FY2025 annual result came in at -$0.08, up 5.13% from the prior year.
EPS (Basic) slipped to -$0.06 in Q2 2023 per MESO's latest filing, from -$0.05 in the prior quarter.
Over five years, EPS (Basic) peaked at -$0.02 in Q3 2019 and troughed at -$0.12 in Q2 2020.
A 5-year average of -$0.07 and a median of -$0.07 in 2021 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2019 and 2020: EPS (Basic) surged 73.01% in 2019, then slumped 283.64% in 2020.
Over 5 years, EPS (Basic) stood at -$0.09 in 2019, then grew by 4.75% to -$0.09 in 2020, then increased by 8.64% to -$0.08 in 2021, then rose by 16.96% to -$0.07 in 2022, then advanced by 10.78% to -$0.06 in 2023.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.06, -$0.05, and -$0.07 for Q2 2023, Q1 2023, and Q4 2022 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	12.62
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	7.70
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-1.96
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-3.06
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	2.12
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	1.23
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.18
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-0.06
10	Mesoblast	2.24 Bn	2.14 Bn	-	-

Historic Data

Download Data